|
(Health-NewsWire.Net, January 04, 2022 ) Growth in this market is attributed to the growing drug & alcohol consumption and the enforcement of stringent laws mandating drug & alcohol testing, rising regulatory approvals for drug screening products & services. On the other hand, bans on alcohol consumption in Islamic countries and prohibitions on workplace drug testing in specific countries may hinder the growth of this market to a certain extent.
According to the new market research report “Drug Screening Market by Product (Consumables, Urine Testing Devices, Analytical, Breathalyzer, Chromatography, Immunoassay) & Services, Sample Type (Urine, Breath), End User (Workplace, Laboratories, Criminal Justice, Hospitals) – Global Forecast to 2026″, published by MarketsandMarkets™, the global drug screening market is projected to reach USD 11.6 billion by 2026, from USD 5.3 billion in 2021, at a CAGR of 16.8% during the forecast period.
Browse in-depth TOC on “ Drug Screening Market “
153 – Tables
45 – Figures
227 – Pages
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162987773
COVID-19 impact on the drug screening market
COVID-19 has resulted in significant disruptions to businesses and economic activities globally and is expected to have a short-term negative impact on the drug screening market due to limited or non-availability of medical facilities/treatment centers, harm reduction service providers, and the fear of infection transmission. To reduce the strain on the healthcare system and decrease disease transmission, various governments worldwide provided guidelines to postpone or delay non-essential medical and surgical procedures. Restrictions and lockdowns were also imposed in travel, business operations, public gatherings, and shelter-in-place orders, all of which have further impacted market growth.
RESTRAINT: prohibition on workplace drug testing in some countries
Some countries such as Canada, Colombia, Argentina, Chile, and South Africa, consider drug & alcohol testing at the workplace to be a violation of employee privacy. For instance, pre-employment drug testing is only performed in France when physicians recommend the test. In Poland and the Czech Republic, drug & alcohol tests in the workplace are prohibited. In Canada, the Eastern Canadian case laws permit drug & alcohol testing only when workplace operations are inherently dangerous or where drug and alcohol testing is limited to a few special cases.
OPPORTUNITY: Emerging economies
Fingerprint-based drug testing is a relatively new concept that has gained significance due to the COVID-19 pandemic. The coronavirus has made it difficult to execute drug testing in hospitals, labs, and other facilities due to the risk of transmitting the infection. Although fingerprint-based drug screening can help limit the spread of COVID, it is noninvasive, portable, less time-consuming, hygienic, enables social distancing, is user-friendly, and requires no specific preparation for sample collection and handling. This test is very easy to implement whenever and wherever required, thus offering flexible and effective workplace drug testing. The test analyzes small traces of sweat in the fingerprint to detect drug and drug metabolites.
Based on the transplant type, the solid organ transplantation segment accounted for the largest share of this market in 2019.
On the basis of transplant type, the market is categorized into solid organ, stem cell, and soft tissue transplantation. Solid organ transplantation accounted for the largest share of the Transplant Diagnostics Market in 2019. Supportive government regulations to increase organ donations across major healthcare markets, the rising number of chronic diseases/disorders leading to transplantation, and ongoing technological advancements in the field of transplant diagnostics are the key factors supporting the growth of the market for solid organ transplantation.
Request for sample pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=162987773
North America was the largest regional market for drug screening market in 2020.
The drug screening market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2020, North America was the largest regional segment of the overall market with a share of 48.2%, followed by Europe. The dominance of the North American market is attributed to factors such as the growing consumption of illicit drugs, the availability of government funding to curb drug abuse, laws supporting drug screening, the growing burden of accidents due to alcohol impairment, and the presence of key players in the region are driving the growth of the drug screening market in this region.
The prominent players operating in this market include LabCorp (US), Quest Diagnostics (US), Abbott Laboratories (US), OraSure Technologies (US), Alfa Scientific Designs (US), Thermo Fisher Scientific (US), Drägerwerk (Germany), LifeLoc (US), MPD Inc. (US), Omega Laboratories (US), Premier Biotech (US), Psychemedics (US), Roche (Switzerland), Shimadzu (Japan), and Siemens Healthineers (Germany).
Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting
Browse Related Reports:
Drug Discovery Services Market by Process (Target Selection, Validation, Lead Optimization), Type (Medicinal Chemistry, DMPK), Drug Type (Biologics, Small Molecules), Therapeutic (Oncology, Neurology), Company (Tier 1, 2, 3) – Global Forecast to 2025
https://www.marketsandmarkets.com/Market-Reports/drug-discovery-services-market-138732129.html
Therapeutic Drug Monitoring Market by Product (Equipment (Immunoassay Analyzers), Consumables), Technology (Immunoassays, Chromatography-MS), Class of Drugs (Antibiotic Drugs, Bronchodilator Drugs), End User – Global Forecast to 2025
https://www.marketsandmarkets.com/Market-Reports/therapeutic-drug-monitoring-market-155350443.html
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/drug-alcohol-screening-market.asp
Visit Our Web Site: https://www.marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/drug-alcohol-screening.asp
MarketsandMarkets™
Mr. Aashish Mehra
1-888-600-6441
raviraj.tak@marketsandmarkets.com
Source: EmailWire.Com 
|
